Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (CYP2C8) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (CYP2J2), with Kis of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively.
性状
Solid
IC50 & Target[1][2]
CYP2C84.82 μM (Ki)CYP2J25.75 μM (Ki)
体外研究(In Vitro)
Salvianolic acid C is a noncompetitive CYP2C8 inhibitor and a moderate mixed inhibitor of CYP2J2, with Kis of 4.82, 5.75 μM for CYP2C8 and CYP2J2, respectively. 1 and 5 μM Salvianolic acid C (SalC) could significantly inhibit the NO production induced by LPS. Salvianolic acid C decreases the expression of iNOS significantly. Salvianolic acid C inhibits LPS-induced TNF-α, IL-1β, IL-6 and IL-10 overproduction. Salvianolic acid C inhibits LPS-induced NF?κB activation. Salvianolic acid C also increases the expression of Nrf2 and HO-1 in BV2 microglial cells.Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Salvianolic acid C (20 mg/kg) treatment could significantly decrease the escape latency. In addition, SalC (10 and 20 mg/kg) treatment significantly increase the platform crossing number compared with the LPS model group. Systemic administration of Salvianolic acid C down regulates the brain TNF-α, IL-1β and IL-6 levels compared with the model group. The iNOS and COX-2 levels in rat brain cortex and hippocampus are higher than that in the control group, while Salvianolic acid C treatment significantly down regulates the cortex and hippocampus regions. Salvianolic acid C (5, 10 and 20 mg/kg) treatment dose-dependently increases the p-AMPK, Nrf2, HO-1 and NQO1 levels in rat brain cortex and hippocampus.Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature or refrigerated transport.
储存方式
4°C, Sealed and stored away from moisture and light;*In solvent : -80°C, 6 months; -20°C, 1 month (Sealed and stored away from moisture and light);